4-(1-acetamidoethyl)benzoic acid | 223520-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1-acetamidoethyl)benzoic acid
• 英文别名: (+)-4-(1-acetamidoethyl)benzoic acid
• CAS: 223520-72-7；149004-70-6；1082747-35-0
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: VGGHZGMYGRBYIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1-acetamidoethyl)benzoic acid 在 lithium aluminium tetrahydride 、 氯化亚砜 、 硫酸 、 potassium carbonate 作用下， 以 四氢呋喃 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[1-[4-[(4-phenylpiperazin-1-yl)methyl]phenyl]ethyl]acetamide
  参考文献：
  名称：

  Novel DMARDs on the basis of a new concept of dual cytokine regulation, TNF-α suppression and IL-10 augmentation

  摘要：

  A series of arylpiperazine derivatives was synthesized to obtain agents showing apparent therapeutic effects in a chronic inflammatory animal model, starting from a lead possessing potent dual cytokine regulatory activity in vivo. We found a pyrimidylpiperazine derivative 17c showing the dual regulatory activity and an excellent therapeutic effect in an adjuvant-induced arthritis model. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00129-3
• 作为产物：
  描述：

  N-[1-(4-溴苯)乙基]乙酰胺 在 lithium hydroxide monohydrate 、 1,3-双(二苯基膦)丙烷 、 palladium diacetate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 24.0h， 生成 4-(1-acetamidoethyl)benzoic acid
  参考文献：
  名称：

  MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

  摘要：

  这里提供了用于调节甲基修饰酶的药剂、组合物及其用途。

  公开号：

  US20150315148A1

文献信息

• N-heterocyclic substituted benzamide derivatives with antihypertensive activity
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1195372A1

  公开（公告）日：2002-04-10

  Benzamide compounds of the formula wherein each symbol is as defined in the specification, isomers thereof and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions comprising a therapeutically effective amount of this compound and a pharmaceutically acceptable additive, and therapeutic agents for hypertension, therapeutic agents for angina pectoris, therapeutic agent for asthma, therapeutic agents for renal and peripheral circulatory disturbances and inhibitor of cerebral vasospasm, which comprise this compound. The compound of the present invention has strong smooth muscle relaxing action, and shows hypotensive action and cerebral • coronary vasodilating action like conventional calcium antagonists, as well as long-lasting renal and peripheral circulation improving action. Unlike calcium antagonists, it permits oral administration to suppress vascular contraction caused by various agonists, and is useful as a strong and long-acting agent for prophylaxis and treatment of circulatory diseases in coronary, cerebral, renal and peripheral arteries, as a therapeutic agent for hypertension, angina pectoris, and renal and peripheral circulation disorder, an inhibitor of cerebral vasospasm and the like. Moreover, the compound of the present invention is useful as a therapeutic agent for asthma.

  苯甲酰胺化合物的化学式如规范中所定义的每个符号，其异构体和药学上可接受的酸盐。包括该化合物的治疗有效量和药学上可接受的添加剂的药物组合物，以及治疗高血压、心绞痛、哮喘、肾脏和外周循环障碍以及脑血管痉挛抑制剂的治疗剂，其中包括该化合物。本发明的化合物具有强大的平滑肌松弛作用，表现出类似于传统钙拮抗剂的降压作用和脑冠脉扩张作用，以及持久的肾脏和外周循环改善作用。与钙拮抗剂不同，它允许口服给药以抑制各种激动剂引起的血管收缩，并可用作冠状动脉、脑部、肾脏和外周动脉循环疾病的预防和治疗的强效长效药物，作为治疗高血压、心绞痛、肾脏和外周循环障碍的治疗剂，脑血管痉挛抑制剂等。此外，本发明的化合物还可用作哮喘的治疗剂。
• Piperazine compounds and medicinal use thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US20030018034A1

  公开（公告）日：2003-01-23

  The present invention relates to a piperazine compound of the formula 1 wherein R 1 and R 2 are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R 3 , R 4 and R 5 are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R 6 and R 7 are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R 8 and R 9 are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-&agr; production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-&agr; production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-&agr; production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-&agr; mediated diseases.

  本发明涉及一种哌嗪化合物，其化学式为1，其中R1和R2分别为氢、卤素、低碳基、低氧基、氨基、取代氨基、硝基、羟基或氰基，R3、R4和R5分别为氢、卤素、低碳基、低氧基、硝基、氨基、取代氨基或羟基，R6和R7分别为氢、低碳基、被卤素取代的低碳基、芳基烷基、酰基或被卤素取代的低酰基，R8和R9分别为氢或低碳基，Y为低碳基亚烷基等，环A为苯基、嘧啶基、噻唑基、吡啶基、吡唑基或咪唑基，以及其药学上可接受的盐和含有这些化合物的药物制剂。本发明的化合物具有优异的TNF-α产生抑制作用和/或IL-10产生促进作用，并且由于其不具有或仅表现出对中枢神经系统的作用明显降低，因此该化合物可用作高度安全和优越的TNF-α产生抑制剂和/或IL-10产生促进剂，并可用作预防或治疗由异常TNF-α产生引起的各种疾病、可用IL-10治愈的疾病，例如慢性炎症性疾病、急性炎症性疾病、由感染引起的炎症性疾病、自身免疫性疾病、过敏性疾病和TNF-α介导的疾病。
• 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US05478838A1

  公开（公告）日：1995-12-26

  4-Amino(alkyl)cyclohexane-1-carboxamide compounds of the formula (I) ##STR1## wherein each symbol is as defined in the Specification, isomers thereof and pharmaceutically acceptable acid addition salts thereof. The 4-amino(alkyl)cyclohexane-1-carboxamide compounds, isomers thereof and pharmaceutically acceptable acid addition salts thereof of the present invention have potent and long-lasting coronary, cerebral, renal and peripheral blood flow increasing actions and are less toxic, and thus are useful as a potent and long-lasting antihypertensive agent and an agent for the prevention and treatment of diseases in the circulatory organs such as coronary, cerebral, renal and peripheral arteries. Moreover, the compounds of the present invention exhibit inhibitory action on experimental asthma of guinea pigs, which is caused by histamine inhalation, and inhibitory action on contraction of trachea strips isolated from guinea pigs, which is caused by acetylcholine, and thus are useful as therapeutic agents for asthma.

  公式（I）的4-氨基（烷基）环己烷-1-羧酰胺化合物，其中每个符号如规范中所定义，其同分异构体和药学上可接受的酸加盐。本发明的4-氨基（烷基）环己烷-1-羧酰胺化合物，其同分异构体和药学上可接受的酸加盐具有强效和持久的冠状、脑、肾和周围血流增加作用，毒性较小，因此可用作强效和持久的降压剂和预防和治疗冠状、脑、肾和周围动脉等循环器官疾病的药物。此外，本发明的化合物对豚鼠实验性哮喘具有组胺吸入引起的抑制作用和对豚鼠离体气道平滑肌收缩的乙酰胆碱引起的抑制作用，因此可用作哮喘的治疗药物。
• Modulators of methyl modifying enzymes, compositions and uses thereof
  申请人：Constellation Pharmaceuticals, Inc.

  公开号：US09051269B2

  公开（公告）日：2015-06-09

  Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

  本文提供了用于调节甲基修饰酶的代理，其组成和用途。
• A General Photocatalytic Strategy for Nucleophilic Amination of Primary and Secondary Benzylic C–H Bonds
  作者：Madeline E. Ruos、R. Garrison Kinney、Oliver T. Ring、Abigail G. Doyle

  DOI：10.1021/jacs.3c04912

  日期：2023.8.23

  intercepted by a variety of N-centered nucleophiles, including nitriles (Ritter reaction), amides, carbamates, sulfonamides, and azoles, for the construction of pharmaceutically relevant C(sp3)–N bonds under unified reaction conditions. Mechanistic studies indicate that HAT is amidyl radical-mediated and that the photocatalyst operates via a reductive quenching pathway. These findings establish a mild, metal-free

  我们报告了一种可见光光氧化还原催化的方法，该方法能够使伯和仲苄基 C(sp 3 )–H 键发生亲核胺化。一种新型酰胺基自由基前体和有机光催化剂串联作用，通过顺序氢原子转移（HAT）和氧化自由基-极性交叉将伯和仲苄基C(sp 3 )–H键转化为碳正离子。生成的碳正离子可以被各种以N为中心的亲核试剂拦截，包括腈（Ritter 反应）、酰胺、氨基甲酸酯、磺酰胺和唑类，以便在统一的反应条件下构建药物相关的 C(sp 3 ) –N键。机理研究表明，HAT 是酰胺自由基介导的，并且光催化剂通过还原猝灭途径发挥作用。这些发现建立了一种温和、无金属和模块化的方案，用于将 C(sp 3 )–H 键快速多样化至胺化产物库。